A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer

Zengliu Su, Dora Dias-Santagata, MarKeesa Duke, Katherine Hutchinson, Ya Lun Lin, Darrell R. Borger, Christine H. Chung, Pierre P. Massion, Cindy L. Vnencak-Jones, A. John Iafrate, William Pao

Research output: Contribution to journalArticle

Abstract

The identification of somatically acquired tumor mutations is increasingly important in the clinical management of cancer because the sensitivity of targeted drugs is related to the genetic makeup of individual tumors. Thus, mutational profiles of tumors can help prioritize anticancer therapy.We report herein the development and validation of two multiplexed assays designed to detect in DNA from FFPE tissue more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted therapies in lung cancer. The platform involves two methods: a screen (SNaPshot) based on multiplex PCR, primer extension, and capillary electrophoresis that was designed to assess for 38 somatic mutations in eight genes (AKT1, BRAF, EGFR, KRAS, MEK1, NRAS, PIK3CA, and PTEN) and a PCR-based sizing assay that assesses for EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 exon 20 insertions. Both the SNaPshot and sizing assays can be performed rapidly, with minimal amounts of genetic material. Compared with direct sequencing, in which mutant DNA needs to compose 25% or more of the total DNA to easily detect a mutation, the SNaPshot and sizing assays can detect mutations in samples in which mutant DNA composes 1.56% to 12.5% and 1.56% to 6.25% of the total DNA, respectively. These robust, reliable, and relatively inexpensive assays should help accelerate adoption of a genotype-driven approach in the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)74-84
Number of pages11
JournalJournal of Molecular Diagnostics
Volume13
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Mutation
DNA
Exons
Lung Neoplasms
Neoplasms
Genes
Therapeutics
Multiplex Polymerase Chain Reaction
Capillary Electrophoresis
Genotype
Polymerase Chain Reaction
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. / Su, Zengliu; Dias-Santagata, Dora; Duke, MarKeesa; Hutchinson, Katherine; Lin, Ya Lun; Borger, Darrell R.; Chung, Christine H.; Massion, Pierre P.; Vnencak-Jones, Cindy L.; Iafrate, A. John; Pao, William.

In: Journal of Molecular Diagnostics, Vol. 13, No. 1, 01.2011, p. 74-84.

Research output: Contribution to journalArticle

Su, Z, Dias-Santagata, D, Duke, M, Hutchinson, K, Lin, YL, Borger, DR, Chung, CH, Massion, PP, Vnencak-Jones, CL, Iafrate, AJ & Pao, W 2011, 'A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer', Journal of Molecular Diagnostics, vol. 13, no. 1, pp. 74-84. https://doi.org/10.1016/j.jmoldx.2010.11.010
Su, Zengliu ; Dias-Santagata, Dora ; Duke, MarKeesa ; Hutchinson, Katherine ; Lin, Ya Lun ; Borger, Darrell R. ; Chung, Christine H. ; Massion, Pierre P. ; Vnencak-Jones, Cindy L. ; Iafrate, A. John ; Pao, William. / A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. In: Journal of Molecular Diagnostics. 2011 ; Vol. 13, No. 1. pp. 74-84.
@article{3891da350f8443b4b7dd6145517567b3,
title = "A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer",
abstract = "The identification of somatically acquired tumor mutations is increasingly important in the clinical management of cancer because the sensitivity of targeted drugs is related to the genetic makeup of individual tumors. Thus, mutational profiles of tumors can help prioritize anticancer therapy.We report herein the development and validation of two multiplexed assays designed to detect in DNA from FFPE tissue more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted therapies in lung cancer. The platform involves two methods: a screen (SNaPshot) based on multiplex PCR, primer extension, and capillary electrophoresis that was designed to assess for 38 somatic mutations in eight genes (AKT1, BRAF, EGFR, KRAS, MEK1, NRAS, PIK3CA, and PTEN) and a PCR-based sizing assay that assesses for EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 exon 20 insertions. Both the SNaPshot and sizing assays can be performed rapidly, with minimal amounts of genetic material. Compared with direct sequencing, in which mutant DNA needs to compose 25{\%} or more of the total DNA to easily detect a mutation, the SNaPshot and sizing assays can detect mutations in samples in which mutant DNA composes 1.56{\%} to 12.5{\%} and 1.56{\%} to 6.25{\%} of the total DNA, respectively. These robust, reliable, and relatively inexpensive assays should help accelerate adoption of a genotype-driven approach in the treatment of lung cancer.",
author = "Zengliu Su and Dora Dias-Santagata and MarKeesa Duke and Katherine Hutchinson and Lin, {Ya Lun} and Borger, {Darrell R.} and Chung, {Christine H.} and Massion, {Pierre P.} and Vnencak-Jones, {Cindy L.} and Iafrate, {A. John} and William Pao",
year = "2011",
month = "1",
doi = "10.1016/j.jmoldx.2010.11.010",
language = "English (US)",
volume = "13",
pages = "74--84",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "1",

}

TY - JOUR

T1 - A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer

AU - Su, Zengliu

AU - Dias-Santagata, Dora

AU - Duke, MarKeesa

AU - Hutchinson, Katherine

AU - Lin, Ya Lun

AU - Borger, Darrell R.

AU - Chung, Christine H.

AU - Massion, Pierre P.

AU - Vnencak-Jones, Cindy L.

AU - Iafrate, A. John

AU - Pao, William

PY - 2011/1

Y1 - 2011/1

N2 - The identification of somatically acquired tumor mutations is increasingly important in the clinical management of cancer because the sensitivity of targeted drugs is related to the genetic makeup of individual tumors. Thus, mutational profiles of tumors can help prioritize anticancer therapy.We report herein the development and validation of two multiplexed assays designed to detect in DNA from FFPE tissue more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted therapies in lung cancer. The platform involves two methods: a screen (SNaPshot) based on multiplex PCR, primer extension, and capillary electrophoresis that was designed to assess for 38 somatic mutations in eight genes (AKT1, BRAF, EGFR, KRAS, MEK1, NRAS, PIK3CA, and PTEN) and a PCR-based sizing assay that assesses for EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 exon 20 insertions. Both the SNaPshot and sizing assays can be performed rapidly, with minimal amounts of genetic material. Compared with direct sequencing, in which mutant DNA needs to compose 25% or more of the total DNA to easily detect a mutation, the SNaPshot and sizing assays can detect mutations in samples in which mutant DNA composes 1.56% to 12.5% and 1.56% to 6.25% of the total DNA, respectively. These robust, reliable, and relatively inexpensive assays should help accelerate adoption of a genotype-driven approach in the treatment of lung cancer.

AB - The identification of somatically acquired tumor mutations is increasingly important in the clinical management of cancer because the sensitivity of targeted drugs is related to the genetic makeup of individual tumors. Thus, mutational profiles of tumors can help prioritize anticancer therapy.We report herein the development and validation of two multiplexed assays designed to detect in DNA from FFPE tissue more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted therapies in lung cancer. The platform involves two methods: a screen (SNaPshot) based on multiplex PCR, primer extension, and capillary electrophoresis that was designed to assess for 38 somatic mutations in eight genes (AKT1, BRAF, EGFR, KRAS, MEK1, NRAS, PIK3CA, and PTEN) and a PCR-based sizing assay that assesses for EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 exon 20 insertions. Both the SNaPshot and sizing assays can be performed rapidly, with minimal amounts of genetic material. Compared with direct sequencing, in which mutant DNA needs to compose 25% or more of the total DNA to easily detect a mutation, the SNaPshot and sizing assays can detect mutations in samples in which mutant DNA composes 1.56% to 12.5% and 1.56% to 6.25% of the total DNA, respectively. These robust, reliable, and relatively inexpensive assays should help accelerate adoption of a genotype-driven approach in the treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=78651079558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651079558&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2010.11.010

DO - 10.1016/j.jmoldx.2010.11.010

M3 - Article

C2 - 21227397

AN - SCOPUS:78651079558

VL - 13

SP - 74

EP - 84

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 1

ER -